IMMIPRINT
DEAD

Serial Number

85082509

Owner

ProteinLogic Limited

Attorney

Howard N. Aronson

Filing Date

Jul 12, 2010

Add to watchlist:

No watchlists yet
View on USPTO

IMMIPRINT Trademark

Serial Number: 85082509

IMMIPRINT is a trademark filed by ProteinLogic Limited on July 12, 2010. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

ProteinLogic Limited (3 trademarks)

Shakespeare House, 42 Newmarket Road
Cambridge CB58EP , GB

Entity Type: 03

Trademark Details

Filing Date

July 12, 2010

Registration Date

Not Registered

Published for Opposition

September 20, 2011

Goods & Services

Medical and veterinary diagnostic test set-ups composed primarily of chemical and/or biochemical reagents used in diagnosing human and animal diseases; diagnostic preparations for medical and veterinary purposes; chemical reagents for medical or veterinary purposes; reagents for medical or veterinary diagnostic purposes

Chemical and biochemical assays and reagents for use in science, industrial research and medical research

Medical analyses, namely, RNA or DNA analyses for diagnosing human and animal diseases and forecasting the expected progress of human and animal diseases, all provided during the course of medical treatment or diagnosis and not for medical research purposes

Apparatus for clinical, medical and veterinary diagnosis, namely, microplate readers for blood and body fluid based diagnostic testing, antibody bio-chips for blood and body fluid based diagnostic testing, flow cytometers for blood and body fluid based diagnostic testing, immuno detectors for blood and body fluid based diagnostic testing, microfluidic biochips for blood and body fluid based diagnostic testing, photometers for blood and body fluid based diagnostic testing, piezo electrical transducers for blood and body fluid based diagnostic testing, acoustic detectors and mass spectrometers for blood and body fluid based diagnostic testing: medical and veterinary testing apparatus for diagnosing human and animal diseases, in particular ones containing chemical and/or biochemical reagents, namely, microplate readers for blood and body fluid based diagnostic testing, antibody bio-chips for blood and body fluid based diagnostic testing, flow cytometers for blood and body fluid based diagnostic testing, immuno detectors for blood and body fluid based diagnostic testing, microfluidic bio-chips for blood and body fluid based diagnostic testing, photometers for blood and body fluid based diagnostic testing, piezo electrical transducers for blood and body fluid based diagnostic testing, acoustic detectors and mass spectrometers for blood and body fluid based diagnostic testing; laboratory apparatus and equipment for use in the detection of soluble CD antigens, soluble immune system proteins and other soluble proteins in bodily fluids all for diagnosis and monitoring of human and animal diseases and for the monitoring of treatments and therapies for human and animal diseases, namely, microplate readers for blood and body fluid based diagnostic testing of one or more disease states in an individual, and monitoring or predicting response to treatments or therapies, and patient stratification, antibody biochips for blood and body fluid based diagnostic testing of one or more disease states in an individual, and monitoring or predicting response to treatments or therapies, and patient stratification, flow cytometers for blood and body fluid based diagnostic testing of one or more disease states in an individual, and monitoring or predicting response to treatments or therapies, and patient stratification, immuno detectors for blood and body fluid based diagnostic testing of one or more disease states in an individual, and monitoring or predicting response to treatments or therapies, and patient stratification, microfluidic bio-chips for blood and body fluid based diagnostic testing of one or more disease states in an individual, and monitoring or predicting response to treatments or therapies, and patient stratification, photometers for blood and body fluid based diagnostic testing of one or more disease states in an individual, and monitoring or predicting response to treatments or therapies, and patient stratification, piezo electrical transducers for blood and body fluid based diagnostic testing of one or more disease states in an individual, and monitoring or predicting response to treatments or therapies, and patient stratification, acoustic detectors and mass spectrometers for blood and body fluid based diagnostic testing of one or more disease states in an individual, and monitoring or predicting response to treatments or therapies, and patient stratification; scientific apparatus and equipment for use in the detection of soluble CD antigens, soluble immune system proteins and other soluble proteins in bodily fluids all for use in the diagnosis and monitoring of human and animal diseases and for the monitoring of treatments and therapies for human and animal diseases, namely, microplate readers for blood and body fluid based diagnostic testing of one or more disease states in an individual, and monitoring or predicting response to treatments or therapies, and patient stratification, antibody bio-chips for blood and body fluid based diagnostic testing of one or more disease states in an individual, and monitoring or predicting response to treatments or therapies, and patient stratification, flow cytometers for blood and body fluid based diagnostic testing of one or more disease states in an individual, and monitoring or predicting response to treatments or therapies, and patient stratification, immuno detectors for blood and body fluid based diagnostic testing of one or more disease states in an individual, and monitoring or predicting response to treatments or therapies, and patient stratification, microfluidic bio-chips for blood and body fluid based diagnostic testing of one or more disease states in an individual, and monitoring or predicting response to treatments or therapies, and patient stratification, photometers for blood and body fluid based diagnostic testing of one or more disease states in an individual, and monitoring or predicting response to treatments or therapies, and patient stratification, piezo electrical transducers for blood and body fluid based diagnostic testing of one or more disease states in an individual, and monitoring or predicting response to treatments or therapies, and patient stratification, acoustic detectors and mass spectrometers for blood and body fluid based diagnostic testing of one or more disease states in an individual, and monitoring or predicting response to treatments or therapies, and patient stratification

Filing History

ABANDONMENT NOTICE MAILED - AFTER PUBLICATION
Nov 14, 2013 MAB5
ABANDONMENT - AFTER PUBLICATION
Nov 14, 2013 ABN5
TEAS EXPRESS ABANDONMENT RECEIVED
Nov 13, 2013 EXAR
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 16, 2013 EXRA
SOU EXTENSION 3 GRANTED
May 15, 2013 EX3G
SOU EXTENSION 3 FILED
May 10, 2013 EXT3
SOU TEAS EXTENSION RECEIVED
May 10, 2013 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 14, 2012 EXRA
SOU EXTENSION 2 GRANTED
Nov 13, 2012 EX2G
SOU EXTENSION 2 FILED
Nov 9, 2012 EXT2
SOU TEAS EXTENSION RECEIVED
Nov 9, 2012 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 22, 2012 EXRA
SOU EXTENSION 1 GRANTED
May 18, 2012 EX1G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
May 18, 2012 AITU
SOU EXTENSION 1 FILED
Apr 26, 2012 EXT1
SOU TEAS EXTENSION RECEIVED
Apr 26, 2012 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Nov 15, 2011 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 20, 2011 NPUB
PUBLISHED FOR OPPOSITION
Sep 20, 2011 PUBO
LAW OFFICE PUBLICATION REVIEW COMPLETED
Aug 17, 2011 PREV
ASSIGNED TO LIE
Aug 8, 2011 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 26, 2011 CNSA
EXAMINER'S AMENDMENT ENTERED
Jul 26, 2011 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jul 26, 2011 GNEN
EXAMINERS AMENDMENT E-MAILED
Jul 26, 2011 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jul 26, 2011 CNEA
NOTIFICATION OF FINAL REFUSAL EMAILED
Feb 7, 2011 GNFN
FINAL REFUSAL E-MAILED
Feb 7, 2011 GNFR
FINAL REFUSAL WRITTEN
Feb 7, 2011 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 18, 2011 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 17, 2011 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 17, 2011 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Oct 25, 2010 GNRN
NON-FINAL ACTION E-MAILED
Oct 25, 2010 GNRT
NON-FINAL ACTION WRITTEN
Oct 25, 2010 CNRT
ASSIGNED TO EXAMINER
Oct 25, 2010 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 15, 2010 NWOS
NEW APPLICATION ENTERED
Jul 15, 2010 NWAP